@inproceedings{PetersKrebs, author = {Peters, F. and Krebs, Irene}, title = {Rechtsmodellierung: Das Apriori beim Verwaltungs-Engineering, demonstriert am Beispiel der Datenschutzkontrolle}, series = {Transformation juristischer Sprachen, Tagungsband des 15. Internationalen Rechtsinformatik Symposions IRIS 2012}, booktitle = {Transformation juristischer Sprachen, Tagungsband des 15. Internationalen Rechtsinformatik Symposions IRIS 2012}, editor = {Schweighofer, Erich and Kummer, Franz and H{\"o}tzendorfer, Walter}, publisher = {{\"O}sterreichische Computer Gesellschaft}, address = {Wien}, isbn = {978-3-85403-288-5}, pages = {143 -- 148}, language = {de} } @misc{VerbruggeAlAssarafetal., author = {Verbrugge, Sue Ellen and Al, Marjon and Assaraf, Yehuda G. and Kammerer, Sarah and Chandrupatla, Durga and Honeywell, Richard and Musters, Rene and Giovannetti, Elisa and O`Toole, Tom and Scheffer, George L. and Krige, David and Gruijl, Tanja de and Niessen, Hans W.M. and Lems, Willem F. and Kramer, Pieternella A. and Scheper, Rik J. and Cloos, Jacqueline and Ossenkoppele, Gert and Peters, Godefridus J. and Jansen, Gerrit}, title = {Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: Down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR}, series = {OncoTarget : open access impact journal}, volume = {7}, journal = {OncoTarget : open access impact journal}, number = {5}, issn = {1949-2553}, doi = {10.18632/oncotarget.6169}, pages = {5240 -- 5257}, abstract = {Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally available hydrophobic aminopeptidase inhibitor prodrug with an esterase-sensitive motif, in myeloid leukemia cells. CHR2863 enters cells by diffusion and is retained therein upon esterase activity-mediated conversion to its hydrophilic active metabolite drug CHR6768, thereby exerting amino acid depletion. Carboxylesterases (CES) serve as candidate prodrug activating enzymes given CES1 expression in acute myeloid leukemia specimens. We established two novel myeloid leukemia sublines U937/CHR2863(200) and U937/CHR2863(5uM), with low (14-fold) and high level (270-fold) CHR2863 resistance. The latter drug resistant cells displayed: (i) complete loss of CES1-mediated drug activation associated with down-regulation of CES1 mRNA and protein, (ii) marked retention/sequestration of the prodrug, (iii) a substantial increase in intracellular lipid droplets, and (iv) a dominant activation of the pro-survival Akt/mTOR pathway. Remarkably, the latter feature coincided with a gain of sensitivity to the mTOR inhibitor rapamycin. These finding delineate the molecular basis of CHR2863 resistance and offer a novel modality to overcome this drug resistance in myeloid leukemia cells.}, language = {en} } @misc{BuchananCuccoloHeymanetal., author = {Buchanan, Erin M. and Cuccolo, Kelly and Heyman, Tom and van Berkel, Niels and Coles, Nicholas A. and Iyer, Aishwarya and Peters, Kim and van 't Veer, A. E. and Montefinese, Maria and Maxwell, Nicholas P. and Taylor, Jack E. and Valentine, Kathrene D. and Arriaga, Patr{\´i}cia and Barzykowski, Krystian and Boucher, Leanne and Collins, W. Matthew and Vaidis, David C. and Aczel, Balazs and Al-Hoorie, Ali H. and Ambrosini, Ettore and Besson, Th{\´e}o and Burin, Debora I. and Butt, Muhammad Mussaffa and Clarke, A. J. Benjamin and Daryani, Yalda and El-Dakhs, Dina Abdel Salam and Elsherif, Mahmoud M. and Fern{\´a}ndez-L{\´o}pez, Maria and Ferreira, Paulo Roberto dos Santos and Freitag, Raquel Meister Ko and Gattei, Carolina A. and Godbersen, Hendrik and Grim, Philip A. and Halama, Peter and Havan, Patrik and Irrazabal, Natalia C. and Isloi, Chris and Iversen, Rebecca Kvisler and Julliard, Yoann and Karaaslan, Aslan and Koh{\´u}t, Michal and Koh{\´u}tov{\´a}, Veronika and Kos, Julija and Kosachenko, Alexandra I. and Lima, Tiago Jess{\´e} Souza de and Mak, Matthew H. C. and Manouilidou, Christina and Marciaga, Leonardo A. and Melinna, Xiaolin Melinna and Miranda, Jacob Francisco and Morvinski, Coby and Muppoor, Aishwarya and M{\"u}jdeci, F. Elif and Nielsen, Yngwie A. and Oliveros, Juan Carlos and Onič, Jaš and Papadatou-Pastou, Marietta and Patel, Ishani and Pavlović, Zoran and Pažon, Blaž and Pfuhl, Gerit and Pronizius, Ekaterina and Roettger, Timo B. and Ronderos, Camilo R. and Ruiz-Fernandez, Susana and Senderecka, Magdalena}, title = {Measuring the semantic priming effect across many languages}, series = {Nature human behaviour}, volume = {10}, journal = {Nature human behaviour}, number = {1}, publisher = {Springer Science and Business Media LLC}, address = {London}, issn = {2397-3374}, doi = {10.1038/s41562-025-02254-x}, pages = {182 -- 201}, abstract = {Semantic priming has been studied for nearly 50 years across various experimental manipulations and theoretical frameworks. Although previous studies provide insight into the cognitive underpinnings of semantic representations, they have suffered from small sample sizes and a lack of linguistic and cultural diversity. In this Registered Report, we measured the size and the variability of the semantic priming effect across 19 languages (n = 25,163 participants analysed) by creating the largest available database of semantic priming values using an adaptive sampling procedure. We found evidence for semantic priming in terms of differences in response latencies between related word-pair conditions and unrelated word-pair conditions. Model comparisons showed that the inclusion of a random intercept for language improved model fit, providing support for variability in semantic priming across languages. This study highlights the robustness and variability of semantic priming across languages and provides a rich, linguistically diverse dataset for further analysis. The Stage 1 protocol for this Registered Report was accepted in principle on 15 July 2022. The protocol, as accepted by the journal, can be found at https://osf.io/u5bp6 (registration) or https://osf.io/q4fjy (preprint version 6, 31 May 2022).}, language = {en} }